Vyleesi Compassionate Use and Expanded Access: What Patients Need to Know in 2026

Why There Is No Active Compassionate-Use Program for Vyleesi

Compassionate use and expanded access exist for drugs that have not yet received FDA approval, or for approved drugs in unapproved populations facing serious or life-threatening conditions. Vyleesi received full FDA approval on June 21, 2019, under NDA 210557, for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] Because a commercially marketed product is available, the legal framework for expanded access under 21 CFR Part 312, Subpart I does not apply to routine prescribing. [2]

HSDD itself is not classified as a life-threatening condition. That classification matters because the FDA's expanded-access pathway prioritizes patients with "serious or immediately life-threatening" diseases under 21 USC 360bbb. [2] Patients with HSDD who cannot afford or access Vyleesi through normal channels do not meet that threshold.

Palatin Technologies, the original developer, completed its commercial partnership transfer to AMAG Pharmaceuticals (subsequently acquired by Cosette Pharmaceuticals). No compassionate-use IND has been registered on ClinicalTrials.gov for bremelanotide since 2020.

What "Expanded Access" Actually Means

The FDA defines three expanded-access categories: individual patient access (including emergency use), intermediate-size patient populations, and widespread treatment IND or protocol. [2] All three require that the drug not be approved for the condition being treated, or that the patient cannot be enrolled in a clinical trial. Neither applies to a premenopausal woman with HSDD who can receive a standard commercial prescription.

When Expanded Access Could Theoretically Apply

One narrow scenario remains: a post-menopausal woman or a male patient with an off-label HSDD diagnosis may theoretically pursue a single-patient IND. The 2023 FDA guidance on expanded access encourages physicians to submit Form FDA 3926 for such situations. [2] In practice, no published case reports document this pathway for bremelanotide as of this writing.

The FDA Approval That Closed the Compassionate-Use Door

The key approval rested on the two Phase 3 RECONNECT trials (Studies B and C), which enrolled a combined 1,267 premenopausal women with generalized acquired HSDD. [3] Participants self-administered bremelanotide 1.75 mg subcutaneously as needed for 24 weeks.

Primary Endpoints in RECONNECT

In RECONNECT Study B, bremelanotide produced a statistically significant improvement in the Female Sexual Function Index desire domain score versus placebo (least-squares mean difference +0.4, P<0.001). The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item-13 score also improved significantly. [3]

RECONNECT Study C replicated these findings with a comparable effect size. The FDA reviewers noted that the absolute magnitude of improvement was modest but clinically meaningful to patients who reported distress from low desire. [1]

Safety Profile That Influences Access Decisions

Nausea occurred in 40.5% of bremelanotide-treated women versus 1.2% placebo in the pooled RECONNECT population. [3] Transient blood pressure increases (mean systolic +1.7 mmHg at 12 hours post-dose) were documented. [1] These findings mean that prescribers may request baseline cardiovascular assessment, which adds a clinical visit cost that patients should factor into total access costs.

Real Pathways to Lower-Cost Vyleesi in 2026

Because expanded access is not available, patients seeking affordable bremelanotide must work within the commercial system. The following pathways are ordered from highest to lowest typical savings.

1. Manufacturer Savings Card (Cosette Pharmaceuticals)

Cosette Pharmaceuticals has maintained a savings card program for commercially insured patients. Eligible patients with private insurance may pay as little as $0 for their first fill, with subsequent fills subject to a monthly cap (historically $50, $75 per fill, though program terms change). Patients on Medicaid, Medicare, or any federal or state government-funded insurance are not eligible for manufacturer cards under the Anti-Kickback Statute safe-harbor rules. [4]

To enroll, visit the official Vyleesi website or ask the dispensing pharmacist to run the BIN/PCN from the savings card. The card works at retail pharmacies and some specialty pharmacies.

2. Patient Assistance Programs

For uninsured or underinsured patients who do not qualify for the manufacturer savings card, patient assistance programs (PAPs) may provide free or low-cost medication. Cosette's PAP eligibility criteria typically include income thresholds at or below 400 to 600% of the federal poverty level. [5] Applications require proof of income, a prescriber attestation, and a completed enrollment form submitted directly to the manufacturer.

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) aggregate PAP listings but are not on the HealthRX citation allow-list; confirm all program details directly with the manufacturer.

3. Pharmacy Discount Programs (GoodRx, Mark Cuban Cost Plus Drugs)

GoodRx and similar discount aggregators negotiate directly with pharmacy benefit managers. As of late 2025, GoodRx coupons for a 4-pack of Vyleesi auto-injectors were quoted at approximately $650, $750 at major chains, compared to an average retail price near $950. [6] These coupons cannot be combined with insurance.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not list bremelanotide in its current formulary, because the drug is still under patent protection (US patent 7,655,658, expiry estimated 2027 to 2029). Generic entry is not expected before 2028 at the earliest.

4. Telehealth Prescribing and Mail-Order Pharmacies

Telehealth platforms can prescribe Vyleesi after a synchronous video visit in all states that permit audio-visual prescribing of non-controlled substances. Because bremelanotide is not a controlled substance under the DEA Controlled Substances Act, the Ryan Haight Online Pharmacy Consumer Protection Act restrictions that apply to scheduled drugs do not limit its telehealth prescribing. [7]

Telehealth prescribing benefits access in two ways. First, it eliminates the cost of an in-office visit for patients in rural areas. Second, telehealth prescribers can route prescriptions to mail-order pharmacies that offer lower dispensing fees, sometimes saving $80, $150 per fill versus retail.

5. HSA and FSA Payment

Vyleesi qualifies for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA) as an FDA-approved prescription medication. The IRS defines eligible HSA expenses under Section 213(d) of the Internal Revenue Code; prescription drugs explicitly qualify. [8] Using pre-tax dollars effectively reduces the cost by the patient's marginal tax rate (22 to 37% for most working adults with HSAs).

An FSA cannot be used to purchase over-the-counter drugs without a prescription, but because Vyleesi requires a prescription, this restriction does not apply. [8]

6. Insurance Coverage Appeals

Most commercial insurance plans classify Vyleesi as a Tier 3 or Tier 4 drug, resulting in copays of $150, $300 per fill without a savings card. [9] Patients whose plans deny coverage may file a formulary exception request supported by:

• A letter of medical necessity from the prescribing physician citing the FSDS-DAO score
• Documentation that the patient meets the FDA-approved indication (premenopausal, generalized, acquired HSDD)
• Evidence that first-line behavioral or sex therapy was considered

The APA's DSM-5 diagnostic criteria for Female Sexual Interest/Arousal Disorder (FSIAD) overlap substantially with the FDA's HSDD indication. [10] Some insurers use DSM-5 coding (F52.0, Hypoactive sexual desire dysfunction) for prior authorization; confirming the correct ICD-10 code with the prescriber before submitting the claim avoids common denial reasons.

Clinical Context: Why Bremelanotide Is Prescribed Over Alternatives

Vyleesi and flibanserin (Addyi, 100 mg oral at bedtime daily) are the only two FDA-approved pharmacologic treatments for HSDD in premenopausal women as of 2026. [1] The two drugs differ mechanistically and practically.

Mechanism of Action

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with MC4R activation in the central nervous system considered the primary driver of pro-sexual signaling. [11] Flibanserin, by contrast, is a multimodal serotonin receptor agonist/antagonist that requires daily dosing and carries a boxed warning for hypotension when combined with alcohol. [12]

Dosing Practicality

Vyleesi is dosed as-needed: one 1.75 mg auto-injector subcutaneously in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. Patients may not use more than one dose within 24 hours and no more than one dose every 24 hours. [1] The as-needed schedule means a 4-pack supply may last several weeks to several months depending on frequency of use, which affects the real per-use cost calculation.

Who Chooses Vyleesi Over Flibanserin

Patients who drink alcohol and do not want to abstain typically prefer bremelanotide. A 2021 network meta-analysis published in the Journal of Sexual Medicine found that bremelanotide and flibanserin produced comparable improvements in desire scores, with bremelanotide carrying a higher rate of nausea and flibanserin carrying a higher rate of CNS adverse events. [13] The prescribing decision often reduces to tolerability preference and lifestyle factors rather than efficacy differences.

Navigating Insurance Prior Authorization for Vyleesi

Prior authorization (PA) is required by the majority of commercial plans that include Vyleesi on formulary. The PA process typically takes 3 to 10 business days. Denial rates are substantial: a 2022 American Medical Association survey found that 35% of physicians reported PA denials for medications they considered medically necessary, with mental and sexual health drugs among the most commonly denied categories. [14]

Step Therapy Requirements

Some plans require documented failure of at least one course of psychotherapy or couples counseling before approving Vyleesi. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that psychological interventions should be considered alongside pharmacologic treatment, not necessarily before it. [15] This guideline language can support a step-therapy exception request.

Expedited PA and Peer-to-Peer Review

If the standard PA is denied, the prescriber may request a peer-to-peer (P2P) call with the insurance medical director within 24 to 72 hours. Approval rates after P2P review are higher than after initial denial in multiple published analyses of specialty drug access. [14] Patients should ask their prescriber's office whether they will pursue a P2P call if the initial PA is denied.

Off-Label Use and Its Effect on Access

Bremelanotide is approved only for premenopausal women. Prescribing it off-label (for example, in post-menopausal women or in men with hypoactive desire) is legal under FDA regulations but has significant access implications.

Insurance will not cover off-label use without a separate prior authorization based on evidence of clinical necessity. Manufacturer savings cards specifically exclude off-label indications in their terms of service. PAPs evaluate off-label requests case by case.

The evidence base for bremelanotide in post-menopausal women is limited. A small open-label Phase 2 study (N=91) published in Menopause in 2014 showed modest improvements in desire domain scores, but no Phase 3 data exist for this population. [16] Patients and prescribers should weigh the access constraints against the limited evidence when considering off-label use.

Compounded Bremelanotide: Risk, Legality, and FDA Position

Some compounding pharmacies and peptide suppliers market bremelanotide as a research chemical or "PT-141," the preclinical designator. This is a separate access pathway from licensed Vyleesi, and it carries distinct risks.

FDA's Position on Compounded Bremelanotide

The FDA classifies bremelanotide as a "difficult to compound" drug because it is a cyclic peptide requiring precise disulfide bond formation during synthesis. Errors in stereochemistry can produce compounds with different receptor binding profiles. [17] The FDA has not placed bremelanotide on its 503A or 503B bulking agent lists as of 2026, meaning licensed compounding pharmacies cannot legally compound it for human use without a patient-specific medical need that the commercial product cannot meet. [17]

Peptide Vendor Risk

Bremelanotide sold as "PT-141" through online peptide vendors is sold "for research use only" and is not FDA-regulated for human administration. Published case series have documented injection-site abscesses, systemic infections, and inconsistent dosing when self-administered peptides from unregulated sources are used. [18] Patients should be counseled that the cost savings from this route are offset by safety and legal risks.

The HealthRX Access Decision Framework for Vyleesi (to be illustrated in review) maps patients across four quadrants based on insurance status (insured vs. Uninsured) and indication status (on-label vs. Off-label), directing each group to the highest-yield access pathway. Insured, on-label patients should pursue savings cards plus PA appeal first. Uninsured, on-label patients should apply to the PAP directly. Off-label patients in either group face the narrowest access and should weigh telehealth-routed HSA/FSA payment as the most reliable low-friction option.

What the Literature Says About HSDD Burden and Treatment Access Barriers

Understanding access barriers requires understanding the condition's prevalence. A 2018 population-based study in JAMA Internal Medicine estimated that 8.9% of women ages 18 to 44 reported distressing low sexual desire meeting HSDD criteria. [19] At that prevalence, approximately 6.5 million premenopausal US women could meet the approved indication.

Despite this burden, post-approval uptake of Vyleesi has been limited. A 2021 JAMA commentary noted that prescriptions for both approved HSDD drugs (flibanserin and bremelanotide) remained well below projections, attributing the gap to cost, prior authorization burden, and clinician unfamiliarity with the indication. [20] The commentary's authors wrote: "The FDA approval of treatments for HSDD has not translated into equitable prescribing, and access barriers, particularly insurance coverage restrictions, remain the primary obstacle to treatment." [20]

A separate 2022 analysis in the Journal of Women's Health found that Black and Hispanic women with HSDD were significantly less likely to receive a prescription for either FDA-approved therapy compared to White women, even after adjusting for income and insurance status (adjusted OR 0.61, 95% CI 0.44 to 0.84, P<0.01). [21] These disparities compound the access problems that cost-reduction programs are designed to address.

Step-by-Step Access Checklist for New Patients in 2026

The following sequence minimizes time-to-treatment and out-of-pocket cost for a premenopausal woman with an established HSDD diagnosis.

Step 1: Confirm the Diagnosis

A formal diagnosis using the FSDS-DAO questionnaire and DSM-5/ICD-10 F52.0 coding is required for most prior authorization forms. The Endocrine Society guideline recommends ruling out contributing medical causes (thyroid dysfunction, prolactinoma, depression, medication-induced desire suppression) before initiating pharmacologic HSDD treatment. [15]

Step 2: Check Formulary Status Before the Prescription Is Written

Call the pharmacy benefits number on the insurance card and ask for the tier placement and PA requirements for NDC 69471-0001 (Vyleesi 1.75 mg/0.3 mL auto-injector). Knowing this before the prescription is sent avoids a claim rejection that can delay the fill by 5 to 7 days.

Step 3: Submit Prior Authorization With Full Documentation

Attach FSDS-DAO scores, the DSM-5 criteria summary, and any records of prior psychotherapy or counseling. If step therapy is required and the patient has not yet undergone counseling, schedule a sex therapy consultation simultaneously. Most PA reviewers accept a referral appointment as evidence of initiation.

Step 4: Apply for the Savings Card in Parallel

The savings card enrollment takes approximately 5 minutes online and can be completed before the PA decision arrives. If the PA is approved and the patient has private insurance, the card applies at the pharmacy counter on the first fill.

Step 5: If PA Is Denied, Request P2P Review Within 24 Hours

Delays beyond 72 hours reduce P2P approval rates. The prescriber should reference the Endocrine Society 2019 guideline [15] and the RECONNECT Phase 3 data [3] during the call.

FAQ